-
Life is about time and timing when living with Duchenne
As a family living with Duchenne, time is everything to us. Decades of trials and […]
-
How I measure my quality of life as someone with LGMD
Since I began writing for Bionews, the parent company of Muscular Dystrophy News Today, I’ve […]
-
How I’ve learned to embrace the highs and lows of caregiving
In the past few weeks, as I’ve sat down at my laptop to write my […]
-
Percheron Therapeutics ends clinical trial in Australia and Europe after data indicates no benefits after 6 months of treatment with avicursen (ATL1102)
Australian company Percheron Therapeutics released topline 6-month data from its Phase 2 study of avicursen […]
-
Support PPMD’s commitment to moving the science further, faster
Greetings from Indiana! I write today letting you know that thanks to a generous pledge […]
-
Over 20 new MDA grants will fund research into muscle diseases
The Muscular Dystrophy Association (MDA) has awarded nearly two dozen new grants to fund research […]
-
WATCH: Sevasemten – CANYON Trial Topline Results (Webinar Recording)
Edgewise Therapeutics recently joined PPMD for a breaking news community webinar, during which Edgewise provided […]
-
Your gift to PPMD is a commitment to accelerating progress
As a pediatric neurologist who takes care of children with neuromuscular diseases, I’ve had the […]
-
PPMD Convenes GI, GU, and Swallowing Experts for Two-Day Workshop
Earlier this month, PPMD convened experts from across the country in Columbus, Ohio for a […]
-
Percheron Announces Termination of Phase 2B Study of Avicursen for Duchenne
PPMD is disappointed to learn of Percheron Therapeutics’ recent decision to terminate the company’s ongoing […]
